Table 1.
Levels of CSF protein biomarkers and demographic data
| Aβ1 – 42 (pg/ml) | Total tau (pg/ml) | p‐tau181 (pg/ml) | p‐tau199 (pg/ml) | p‐tau231 (U/ml) | VILIP‐1 (pg/ml) | MMSE | Age | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | Mean ± SD (number of patients) | Median (25–75th percentile) | |
| AD | 539.39 ± 298.92 (113) | 505.51 (308–725.5) | 507.45 ± 372.53 (113) | 507.45 (246.5–652.83) | 79.88 ± 47.96 (112) | 70.94 (55.25–93.65) | 4.37 ± 3.53 (113) | 3.56 (1.72–6.19) | 3.86 ± 5.52 (111) | 1.74 (0.67–3.72) | 137.12 ± 88.58 (111) | 121.73 (57.57–194.87) | 19.83 ± 4.85 (113) | 73 (67–77) |
| MCI | 723.44 ± 371.87 (53) | 679 (398.02–1,023) | 246.44 ± 158.00 (53) | 210 (134.5–330.17) | 57.64 ± 30.86 (51) | 51.96 (36.37–69.08) | 3.40 ± 2.35 (52) | 2.92 (1.37–5.21) | 1.82 ± 3.18 (51) | 0.82 (0.36–1.94) | 94.86 ± 78.11 (50) | 70.12 (27–135.04) | 25.09 ± 2.96 (53) | 70 (59–74) |
| HC | 860.33 ± 497.46 (9) | 1,022 (265–1,315) | 293.33 ± 346.14 (9) | 228 (62–367) | 48.54 ± 26.14 (9) | 55.82 (17.22–70.18) | 1.42 ± 0.96 (9) | 1.42 (0.72–2.42) | 1.29 ± 2.05 (9) | 0.51 (1.67–1.70) | 99.27 ± 70.36 (9) | 109.25 (27–160.30) | 27.43 ± 1.81 (9) | 52 (43–62) |
| FTD | 391.17 ± 175.17 (22) | 381.5 (276.78–532.1) | 502.02 ± 408.99 (22) | 322.02 (201.45–773.57) | 69.62 ± 37.89 (22) | 71.44 (31.76–106.81) | 5.92 ± 5.52 (22) | 4.34 (2.31–7.29) | 1.91 ± 2.34 (22) | 1.05 (0.69–1.93) | 104.21 ± 73.30 (22) | 77.29 (39.95–174.94) | 16.32 ± 5.31 (22) | 61 (56–65) |
| VaD | 502.91 ± 235.95 (14) | 432.13 (364.25–714.7) | 516.31 ± 325.75 (14) | 409.53 (310.73–742.47) | 72.68 ± 36.22 (13) | 72.9 (45.59–111.18) | 5.30 ± 5.51 (14) | 2.89 (1.60–7.89) | 1.44 ± 0.78 (13) | 1.54 (0.79–2.06) | 123.03 ± 78.30 (13) | 105.64 (47.04–173.57) | 23.50 ± 5.04 (14) | 71 (63–77) |
| DLB | 428.32 ± 259.78 (7) | 296.13 (200.68–657.11) | 126.41 ± 44.91 (7) | 130.03 (81.09–153.00) | 41.99 ± 28.84 (7) | 34.24 (25.79–39.98) | 2.48 ± 1.58 (7) | 2.58 (0.89–3.67) | 0.56 ± 0.18 (7) | 0.57 (0.48–0.67) | 47.80 ± 16.90 (7) | 48.02 (29.22–64.23) | 19.29 ± 3.90 (7) | 70 (68–75) |
| AD + VaD | 553.23 ± 37.17 (3) | 535 | 579.67 ± 460.42 (3) | 661 | 74.11 ± 28.57 (3) | 89.49 | 2.84 ± 1.93 (3) | 3.75 | 1.97 ± 1.80 (3) | 2.12 | 108.03 ± 70.19 (3) | 146.88 | 19.33 ± 4.04 (3) | 78 |
| ND | 459.46 ± 194.13 (4) | 465.31 (273.27–639.80) | 230.68 ± 116.96 (4) | 239.30 (118.96–333.78) | 25.48 ± 8.22 (4) | 26.49 (17.19–32.77) | 1.66 ± 1.94 (4) | 1.48 (0.00–3.50) | 0.39 ± 0.27 (4) | 0.42 (0.41–0.63) | 57.26 ± 60.52 (4) | 27 (27–117.78) | 19.25 ± 5.32 (4) | 66 (52–68) |
| PD | 232.08 ± 139.89 (2) | 282.08 | 30.5 ± 43.13 (2) | 30.5 | 20.48 ± 16.33 (2) | 20.48 | 1.26 ± 1.31 (2) | 1.26 | 0.35 ± 0.31 (2) | 0.35 | 27 (2) | 27 | 30 (1) | 78 |
| CBS | 917.56 (1) | 578.28 (1) | 84.3 (1) | 1.66 (1) | 0.81 (1) | 347.62 (1) | 27 (1) | 51 | ||||||
Aβ1–42: amyloid β1–42 protein; AD: Alzheimer's disease; AD + VaD: mixed dementia; CBS: corticobasal syndrome; DLB: dementia with Lewy bodies; FTD: frontotemporal dementia; HC: healthy control; MCI: mild cognitive impairment; ND: nonspecific dementia; p‐tau181: tau protein phosphorylated at threonine 181; p‐tau231: tau protein phosphorylated at threonine 231; p‐tau199: tau protein phosphorylated at serine 199; PD: Parkinson’s disease; SD: standard deviation; VaD: vascular dementia.